Trump Administration Issues New Drug Pricing Executive Order
President Trump issued the “Lowering Drug Prices by Putting America First” executive order on Sept. 13. The new executive order repeals the original and expands the drugs covered by Trump’s proposed “most favored nations” pricing plan to include both Medicare Parts B and D drugs. Under this executive order, Medicare would not pay more for drugs than the lower prices paid by other developed nations.
On July 24, President Trump signed a drug pricing executive order. Though the text of this order was never released, the White House stated that it would peg drug prices for Americans against those in other countries. Trump delayed implementation of the order after Aug. 25 to give pharmaceutical companies time to negotiate with the White House in hopes of reaching an agreement on drug prices. No agreement was reached and, as a result, this new executive order was issued.
The pharmaceutical industry strongly opposes both the July 24 and the Sept. 13 drug pricing executive orders.
The new order calls on the Health and Human Services Secretary Alex Azar to “immediately take appropriate steps to implement his rulemaking plan to test a payment model,” putting in place the “most favored nations” policy.
However, it is unclear if the most recent executive order will take effect prior to the end of President Trump’s current term due to the lengthy rulemaking process that will be required.